This webinar introduces COYA 302, a novel combination biologic immunotherapy that will be evaluated in the ALSTARS Phase 2 clinical trial for amyotrophic lateral sclerosis (ALS). The presentation will provide an overview of the therapeutic mechanism of action, and attendees will learn about the study design being used to assess the safety and efficacy of COYA 302 in ALS patients.
